Free Trial
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

$983.80
-10.15 (-1.02%)
(As of 05/22/2024 ET)
Today's Range
$981.57
$997.87
50-Day Range
$883.20
$993.95
52-Week Range
$684.80
$998.33
Volume
308,641 shs
Average Volume
453,708 shs
Market Capitalization
$108.40 billion
P/E Ratio
29.06
Dividend Yield
N/A
Price Target
$989.36

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.76 Rating Score
Upside/​Downside
0.6% Upside
$989.36 Price Target
Short Interest
Healthy
1.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.69
Upright™ Environmental Score
News Sentiment
0.74mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$53.65 M Sold Last Quarter
Proj. Earnings Growth
8.78%
From $37.34 to $40.62 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.00 out of 5 stars

Medical Sector

179th out of 921 stocks

Pharmaceutical Preparations Industry

61st out of 394 stocks

REGN stock logo

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock Price History

REGN Stock News Headlines

Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).
Will the Biotech Sector Shift From Lagger to Leader? (REGN)
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs.
Regeneron Pharmaceuticals, Inc. (REGN)
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/02/2024
Today
5/22/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
13,450
Year Founded
1988

Price Target and Rating

Average Stock Price Target
$989.36
High Stock Price Target
$1,189.00
Low Stock Price Target
$720.00
Potential Upside/Downside
+0.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.76
Research Coverage
21 Analysts

Profitability

Net Income
$3.95 billion
Pretax Margin
30.85%

Debt

Sales & Book Value

Annual Sales
$13.10 billion
Cash Flow
$43.11 per share
Book Value
$244.96 per share

Miscellaneous

Free Float
100,457,000
Market Cap
$108.40 billion
Optionable
Optionable
Beta
0.17

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives


REGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price target for 2024?

21 analysts have issued 12 month target prices for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $720.00 to $1,189.00. On average, they anticipate the company's stock price to reach $989.36 in the next twelve months. This suggests a possible upside of 0.6% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2024?

Regeneron Pharmaceuticals' stock was trading at $878.29 at the beginning of the year. Since then, REGN shares have increased by 12.0% and is now trading at $983.80.
View the best growth stocks for 2024 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings results on Friday, February, 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. The biopharmaceutical company earned $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a trailing twelve-month return on equity of 16.83%. The firm's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $10.96 EPS.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.14%), Capital World Investors (4.22%), Capital International Investors (2.84%), Price T Rowe Associates Inc. MD (0.82%), Bank of New York Mellon Corp (0.81%) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.37%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
This page (NASDAQ:REGN) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners